On February 29, 2019, the U.S. Food and Drug Administration (FDA) issued a safety communication warning the public about an increased risk of blood clots and death in patients with rheumatoid arthritis taking a high dose of Xeljanz (tofacitinib). The warning was prompted by a mandatory post-marketing safety trial of the drug. The trial is still … [Read more...]